Nifty Pharm index broke a 7-month low, post two of its constituents disappoint specification of the US Food and Drug Administration (USFDA). Shares of Cipla plunged towards its 52-week low of Rs 883.75 after the drug regulator issued eight observations to its Pithampur-based manufacturing unit.
In similar incident, Biocon failed to meet degradation specifications necessitating the recall 3,665 bottles of antifungal medication. On Tuesday, the share price slipped to its new 52-week low.
The broad trend in the Nifty Pharm index has been satisfactory since November last year. The index trades close to 20 per cent lower from its all-time high of 14,938 reached last year.
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.
Subscribe To Insights
Key stories on business-standard.com are available to premium subscribers only.Already a BS Premium subscriber? Log in NOW
Or
Also Read
Sun Pharma.Inds.
- NSE
- BSE
- 1D
- 5D
- 1M
- 3M
- 6M
- 5Y
- MAX